Clinical development

oNKord® for treatment of cancer


The company has focused on the development of a highly reliable and reproducible GMP-compliant process (conform ATMP regulations) for the ex vivo generation of highly pure and functional NK cells from cryopreserved “off-the-shelf" umbilical cord blood (UCB) products. This process can overcome the limitations of current attempts to perform NK cell therapy in patients with AML or other cancer types.

Glycostem believes that oNKord® does not only have the potential to successfully treat AML patients but offers a platform to develop new NK cell-based therapies in other disease areas such as:

Multiple Myeloma and other hematological cancers as well as solid tumours (e.g., colorectal cancer, head-neck cancer, lung cancer and breast cancer).

Subscribe to our newsletter

If you subscribe you agree to the Privacy Notice of Glycostem Therapeutics B.V. as found on the website.